Article reprinted from: Sinoa
As the "second brain of the human body", the health of the gut is closely related to the overall health of the human body. At present, probiotic dietary supplements are receiving more and more attention and attention. In 2020, the Expert Consensus on the Clinical Application of Microecological Regulators in China (2020 Edition) issued by the Microecology Branch of the Chinese Preventive Medicine Association pointed out that the role of probiotics is strain-specific and dose-dependent, and the supplement dose of probiotics is usually limited to the range of 108~1011 CFU. However, the fragile physiological and biochemical properties of probiotics lead to their intolerance to various factors such as temperature, moisture, and stomach digestion environment, which ultimately affects the stability of the product and its effect. Therefore, the development of new complex probiotic preparations that can target the intestinal delivery of high viable bacteria plays an important role in improving product quality and enhancing product value.
Ningbo Sinoya Marine Biotechnology Co., Ltd. has independently developed a new generation of highly active patented microcrystalline ball probiotics - CrystoGen™ microcrystalline ball probiotics (a polysaccharide-producing Bifidobacterium longum variant and its polysaccharides in the preparation of crystal ball probiotics, patent number: ZL 2023 1 0094263.2) Its characteristics of high activity, water and oxygen insulation, targeted delivery, and sustained and controlled release are superior in improving the stability and performance of probiotic products in terms of shelf life. It can better meet the intestinal delivery of probiotics and the sustained and controlled release and colonization of the intestine. On the basis of CrystoGen™ microcrystalline ball probiotics, through continuous breakthroughs in technology, the development of CrystoGen™ microcrystalline ball probiotics suitable for water phase has also been realized, and the application of microcrystalline ball probiotics in liquid preparations such as yogurt and beverages has been expanded.
CrystoGen™ Microcrystalline Sphere Probiotic Technology
The CrystoGen™ microsphere multilayer microencapsulation technology developed by Ningbo Sinoa Marine Biotechnology Co., Ltd. (a polysaccharide-producing Bifidobacterium longum variant and its polysaccharide application in the preparation of polysaccharides, patent number: ZL 2023 1 0094263.2,) has superior performance in improving the shelf life stability and water-soluble stability of strains, which can better meet the strain-specific and dose-dependent needs of probiotic product development.
Its performance is as follows:
1. The number of viable bacteria with high activity can reach 600 billion CFU/g
2. Gastric acid resistance: After entering the body, the microcrystalline ball can effectively resist the erosion of gastric acid and protect the live bacteria in it from destruction, so as to ensure that the live bacteria can reach the intestine smoothly.
3. Sustained intestinal release: slow and controlled release, effective colonization
4. Smaller diameter: particle size 0.5-2.5mm Easy to eat, easy to swallow, convenient for more market applications
5. Water-soluble and stable: The microcrystalline sphere can maintain its structure and activity in water for a long time without losing its effect due to dissolution. This stability helps to ensure the continued action of the microcrystalline spheres in the gut.
6. Embedding of other active substances: Microcrystalline sphere embedding technology can be widely used in the encapsulation of functional foods to achieve water and oxygen insulation, gastric acid tolerance, slow and controlled release control, flavor shielding, reduce the mutual interference of other substances between formulas, etc., and expand the application and development of products.
Ningbo Sinoa company profile
Founded by Dr. Zhu Hui, Ningbo Sinoa Marine Biotechnology Co., Ltd. is committed to the innovative development of marine biological resources and the integrated development of raw materials. The company uses synthetic biology technology to deeply explore marine biological germplasm resources, develops core functional ingredients such as marine enzyme preparations, marine microecological preparations and marine polysaccharides, and combines intestinal sustained and controlled-release complex preparation technology to provide enteral precision nutrition and precision medicine solutions to serve human health.
Core products:
●CrystoGen™高活性晶球益生菌
●Zoomzyme™定制化消化酶
●CrystoLac™ highly active lactase
Business scope: digestive enzyme probiotic raw materials, CrystoGen™ high-activity crystal ball probiotics, ODM
The human body simulates the gastrointestinal digestive system in vitro
The in vitro simulated digestive system is an in vitro model that simulates the digestion process of the human gastrointestinal tract and simulates in vivo digestion and absorption under in vitro conditions, and is used to predict or evaluate the digestibility, bioavailability, release kinetics and structural changes of compounds. The in vitro simulated digestion system can completely or partially replace in vivo experiments, which has the advantages of reducing costs and time, improving experimental repeatability and accuracy, and manual monitoring. The in vitro simulated digestive system can detect the entire digestion process of probiotics in the gastrointestinal tract from time to time, which is helpful for the bioavailability and functional research of probiotic products.
It can provide professional gastrointestinal digestion simulation experiments to help the research of probiotics and functional foods.
Exhibition information
Sinoa Shanghai FIA Exhibition 2024
⏰ When: June 19-21, 2024
Booth: Hall 2.1, 21J15
Location: Shanghai · National Exhibition and Convention Center
All image sources: Sinoa